



**DNAPrint Company Contact:**  
**Richard Gabriel**  
**CEO and President**  
**941-366-3400**

**-or-**

**DNAPrint Investor Contact:**  
**Ron Stabiner**  
**The Wall Street Group, Inc.**  
**212-888-4848**

**CodeAmber Company Contact:**  
**Linda Spagnoli**  
**Director of Communications**  
**772-971-4816**

## **DNAPRINT™ GENOMICS AND CODE AMBER® FORM PARTNERSHIP TO OFFER STORAGE OF DNA SEQUENCING ON AMBER STICK™**

*DNAPrint Also Becomes Sponsor of Code Amber Ticker*

**SARASOTA, Fla., and Mandeville, La., Feb. 13, 2007 – DNAPrint™ Genomics, Inc. (OTCBB: DNAG), and Code Amber® ([www.codeamber.org](http://www.codeamber.org))** today announced a partnership under which consumers would be offered the ability to store a child's DNA sequence on a memory stick for instant accessibility and, at the same time, DNAPrint has become the sponsor of the Code Amber Ticker, a JavaScript news feed ticker that displays active Amber Alerts on an organization's web pages.

In cooperation with Amber Stick™ (<http://codeamber.org/idkits.html?front>), the only child identification system endorsed by Code Amber, DNA sequencing from DNAPrint™ will be stored on a flash memory device, along with photos and descriptions of the child.

Code Amber is the most recognized distributor of Amber Alerts on the Internet. With its powerful reach to more than 300,000 web sites and PCs displaying the Code Amber Ticker, millions are alerted when a child is missing or in imminent danger.

"When children are unintentionally separated from their parents by being lost, abducted or the victim of a disaster, time is critical," said Bryant Harper, President of Code Amber. "With all the identifying information stored safely and accurately in one place, parents can assist law enforcement in the crucial first moments of a reported disappearance. We are proud to have DNAPrint as our sponsor and to offer their dynamic technology to everyone."

DNAPrint™ is a trusted name with law enforcement agencies. They have offered support to international, federal and local authorities with its DNAWitness™ and Ancestry byDNA™ products, including federal cases in California and Louisiana, with local police in the Mammoth Lakes (Calif.) Murder Case, and with New Scotland Yard in the United Kingdom in the case of the so-called Minstead Rapist.

"With our close association with the law enforcement community, we have long known that our products were needed in the public sector," stated DNAPrint™ CEO and President Richard Gabriel. "DNA can be used for more than just identifying suspects, and can be extremely useful in tracking and identifying children after they have gone missing."

(MORE)

Mr. Gabriel continued, “We undertook this sponsorship to provide support for Code Amber. We also see the potential to support the marketing and sales efforts surrounding our consumer products, specifically the Company’s proprietary DNA sequencing and storage products. Code Amber is one of many channels that DNAPrint uses to encourage parents to test and store their children’s DNA for purposes of identifying certain gene markers that would indicate sensitivity to certain treatments for various diseases, such as an allergic reaction to penicillin, and AmberStick is uniquely suited to this purpose in addition to being an aid to finding children when they go missing. We hope that parents everywhere will give serious consideration to availing the services available to them with AmberStick, and we look forward to partnering with Code Amber in the sponsorship of the Code Amber Ticker.”

### **About Code Amber**

Based in Mandeville, La., Code Amber is the most recognized distributor of Amber Alerts on the Internet, reaching over 330,000 web sites and personal computers. A leader in the field of child advocacy, Code Amber offers a range of products and services to law enforcement, media, corporations and the public dealing with Amber Alert notification, child safety and information storage. Code Amber’s signature Java Script Amber Alert Ticker and XML feed are used throughout North America. For more information, visit [www.codeamber.org](http://www.codeamber.org).

### **ABOUT DNAPRINT GENOMICS, INC.**

DNAPrint Genomics, Inc. ([www.dnaprint.com](http://www.dnaprint.com)) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to [www.dnaprint.com](http://www.dnaprint.com) for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

### **Forward-Looking Statements**

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.